Pretreatment of hepatetctomized rats with \textit{Coleus forskohlii} did not interfere with the course of hepatic hyperplasia\textsuperscript{1}

Pedro Paulo Barros\textsuperscript{1} \textsuperscript{D}, Gisele Mara Silva Gonçalves\textsuperscript{1} \textsuperscript{D}, Gustavo Henrique da Silva\textsuperscript{1} \textsuperscript{D}, Ana Laura Masquetti Fava\textsuperscript{2} \textsuperscript{D}

\textsuperscript{1} PhD, Full Professor, Researcher, Faculty of Pharmaceutical Sciences, Pontifícia Universidade Católica de Campinas (PUC-Campinas), Brazil. Conception of the study, interpretation of data, manuscript writing, critical revision.
\textsuperscript{2} Pharmacist, Faculty of Pharmaceutical Sciences, Fundo de Apoio à Iniciação Científica (FAPIC), PUC-Campinas, Brazil. Design of the study.

Abstract

\textbf{Purpose:} \textit{Coleus forskohlii} Briq., a medicinal plant originally from India, has been indicated against heart disease, expiratory disorders, convulsions, and hepatic changes, among others. In view of the broad pharmacological potential of the plant and the scarce information about its effects, the objective of the present study was to investigate the effect of its use for pretreatment of partially hepatetctomized rats.

\textbf{Methods:} The animals were divided into two experimental groups: Control (CG) receiving physiological saline for 10 days before partial hepatetctomy, and Treated (TG) receiving 40 mg \textit{Coleus forskohlii}/kg/day for 10 days before partial hepatectomy. The treatments were performed by gastric gavage. After the surgical procedure, treatment was continued according to the following groups: CG 24 h, CG 48 h, TG 24 h, and TG 48 hs, and liver tissue and intracardiac blood samples were obtained for histological and biochemical analysis, respectively.

\textbf{Results:} No significant differences were observed in mitotic or apoptotic index or in the concentrations of the enzymes AST, ALT and alkaline phosphatase, and no areas of fibrosis were detected.

\textbf{Conclusion:} Treatment with \textit{Coleus forskohlii} did not interfere with the course of hepatic hyperplasia.

\textbf{Key words:} Aspartate Aminotransferases. Alanine Transaminase. Alkaline Phosphatase. Mitosis. Apoptosis. Liver. Rats.
Pretreatment of hepatetctomized rats with Coleus forskohlii did not interfere with the course of hepatic hyperplasia
Barros PP et al.

Introduction

Coleus forskohlii Briq., also known as Plectranthus barbatus, is a plant species belonging to the family Lamiaceae originating from India, which has been used in traditional medicine against heart disease, respiratory and intestinal disorders, convulsions, and liver alterations. The species is widely diffuse in Brazil, where it is popularly called “Falso-Boldo” or “Brazilian boldo” and is used for the treatment of hepatic and digestive disorders.

Magdah Ganash and Sultan Qanash conducted studies on Coleus forskohlii and Plectranthus barbatus in order to quantitate their phenolic acid content and to determine their antitumoral, antioxidant and antimicrobial activity. The authors observed a subtle difference in the activities of the two species possibly due to their different molecular composition and found out that C. forskohlii has antioxidant and antibacterial activities against S. aureus, E.coli and S. tiphy.

Many molecules present in phytotherapeutic agents may have different activities. Ma et al. determined the anti-inflammatory activity of a Coleus forskohlii extract used for the treatment of asthma and of the upper airways due to the modulation of inflammatory cytokines and concluded that this phytotherapeutic compounds can be potentially applied to the treatment of asthmatic conditions. Other studies indicated that the antioxidant potential and other medicinal properties of Coleus forskohlii extract may act as renal protectors and preserving agents against the oxidative deterioration induced by degenerative diseases.

In addition, the extract of C. forskohlii roots is known to contain a diterpene with the property of increasing AMPc concentration by activating adenylate cyclase, which results in various therapeutic effects against idiopathic asthma and congestive cardiomyopathy.

Alasbahi and Melzinga described the pharmacological action of forskolin on the cardiovascular system (increasing coronary blood flow), on the reduction of platelet aggregation, on the digestive system (increasing gastric acid secretion and intestinal smooth muscle relaxation), on the respiratory system (bronchodilator effect), on the genitourinary system (relaxation of the detrusor muscle of the bladder and stimulation of renin secretion by the kidneys), on the eyes (reducing intraocular pressure), and on the skin (increasing melatonin production), in addition to antitumoral activity and maintenance of body weight (AMPc-mediated lipolytic effect).

Recent studies have shown that the potential of forskolin to increase AMPc had involved antiproliferative and antimigratory effects against human pancreatic cells.

Guo et al. demonstrated that forskolin present in Coleus forskohlii may have a protective activity against signs and symptoms of ototoxicity induced by the use of cisplatin. According to these authors, forskolin was able to inhibit the activation of the cellular apoptotic mechanism and the production of reactive oxygen species (ROS).

In view of the broad pharmacological potential of Coleus forskohlii, the objective of the present study was to investigate the effects of pretreatment of partially heptatectomized rats with this phototherapeutic agent on hepatic hyperplasia, considering that such effects are poorly known.

Methods

The experimental protocol of the present study was approved by the Ethics Committee for the Use of Animals of Pontificia Universidade Católica de Campinas (Protocol nº018/2015) and the experiments were conducted according to the Brazilian Directives for the Care and Use of Animals for Teaching or Research Activities.

The methodology of the present study followed that of previous studies by Barros et al. Twenty male Wistar rats weighing 250-260 g were obtained from the Multidisciplinary Animal Experimentation Unit (Animal House) of the University of Campinas, and kept in a room with controlled temperature (22 ± 1°C) under a 12 hour light/dark cycle, with free access to pelleted chow (Nuvilab) and filtered water.

Material

A pharmaceutical grade dry Coleus forskohlii extract was purchased from a local compounding pharmacy (Ao Pharmaceutico, Campinas-SP). Vincristine sulfate was obtained from the Libbs Farmaceutica Laboratory, and the enzymatic assay kits were obtained from LaborLab. All other reagents were analytical grade.

Partial heptatectomy

The animals were divided into groups (n=5) as shown in Table 1. The treatments were performed by daily gastric gavage over a period of 10 days. Next, the animals were submitted to the surgical procedures and treated for 1 or 2 more days according to the group to which they belonged.
Table 1 - Experimental groups and treatments.

| Groups | Treatments |
|--------|------------|
| Control | CG 24 h: Physiological saline/10 days before c |
|         | CG 48 h |
| Treated | TG 24 h: 40 mg Coleus forskohlii/kg/day/10 days before partial hepatectomy |
|         | TG 48 h |

CG 24 h and TG 24 h: treatment continued for 24 hours after partial hepatectomy.
CG 48 h and TG 48 h: treatment continued for 48 hours after partial hepatectomy.

For partial hepatectomy, the animals were anesthetized intraperitoneally with xylazine hydrochloride and ketamine, and approximately 70% of hepatic tissue was removed by the method of Higgins and Anderson. The animals then continued to be treated for 24 or 48 hours after surgery and then submitted to removal of hepatic tissue and blood collection. To this end, vincristine sulfate (1 mg/kg) was administered by intraperitoneal injection in order to block the cell cycle of all hepatocytes in the M phase. The remaining hepatic tissue was then removed under anesthesia, intracardiac blood samples were obtained, and the animals were euthanized.

Histological processing

The procedures were carried out by the method of Barros et al. Hepatic tissue fragments were cut into 7 µm-thick slices and stained with hematoxylin-eosin (HE) and by the Feulgen method (FM). Images were captured digitally using a photomicroscope (Nikon Eclipse E200) coupled to a camera (Nikon Colpix 4500) and mitotic and apoptotic figures were quantitated by microscopic analysis.

Determination of enzymatic activity

The serum enzymatic activities of alanine-aminotransferase (ALT), aspartate-aminotransferase (AST) and alkaline phosphatase (AP) were determined using commercial kits for human samples (LaborLab™) and a UV-VIS spectrophotometer UV-Vis (Varian™). Data analysis

Data are reported based on the number of cells identified by microscopic analysis. Hepatic tissue slides were analyzed in 20 fields which served as the base for the counts of mitotic and apoptotic figures. Morphometry data and AST, ALT and AP were analyzed statistically using the Graph Pad PRISM™ software. The Mann-Whitney test (p<0.05) was used for group comparisons.

Results

Data are reported as means and standard deviation. The apoptotic and mitotic indices did not differ significantly from control for either the 24 or 48 hour period after partial hepatectomy (Fig. 1 a,b). Similarly, no difference was observed for the enzymes AST, ALT and AP (Fig. 1 c-e, respectively).
Pretreatment of hepatetctomized rats with *Coleus forskohlii* did not interfere with the course of hepatic hyperplasia
Barros PP et al.

Acta Cir Bras. 2019;34(6):e201900607

*Discussion*

In order to assess the hepatic hyperplasia occurring after treatment with *Coleus forskohlii*, histological analysis was carried out for the calculation of mitotic and apoptotic indices, in view of the fact that partial hepatectomy induces increased mitosis and at the same time represents tissue injury that may induce apoptosis. When the results for the control and treated groups were compared, no significant difference was observed between them, thus showing that treatment with *Coleus forskohlii* did not affect the mitotic or apoptotic index.

On the other hand, Geng *et al.*\textsuperscript{13} and Jyothi *et al.*\textsuperscript{14}, in a study of the effect of a *Coleus forskohlii* extract on the hepatotoxicity induced by carbon tetrachloride in mice, concluded that this treatment was hepatoprotective. The findings of these authors suggest that the mechanism of action involved in hepatoprotection interfered with the toxicity of carbon tetrachloride. When this result is compared to ours, it can be seen that the hepatoprotection observed by the cited authors was not related to the surgical procedure performed in our study, so that it did not interfere with hepatic hyperplasia after partial hepatectomy.

The data obtained here with the biochemical analyses (AST, ALT and AP) did not show significant differences between the treated and control groups, so that the treatment with *Coleus forskohlii* also did not interfere with the plasma concentrations of these enzymes. This result differed from that reported by Virgona *et al.*\textsuperscript{15}, who supplemented the diet of rats with different concentrations of the *Coleus forskohlii* extract standardized with 10% deforskolin and observed hepatic tissue changes and a dose-dependent increase of plasma AST and ALT. Important results were also obtained by Malarvizhi and Srinivasan\textsuperscript{16}, who treated mice with a *C. forskohlii* extract administered orally and confirmed its antitumoral and hepatoprotective activity. In a review study about the toxicity of ingredients of natural origin, Jakopin\textsuperscript{17} reported that the data available for forskolin, the major compound of *Coleus forskohlii*, indicate that this substance appears to be well tolerated and not to be mutagenic. The author did not mention hepatotoxicity. In the present study, despite the absence of a significant difference, the mean values of the apoptotic index and ALT for the group treated at 24 hours (TG 24 h) were higher than their respective controls (CG 24 h). Although consulted authors consider the extract of *C. forskohlii* to be of safe use, these increases may indicate a possible tendency to the occurrence of liver damage, a fact that requires investigation in future studies.

**Figure 1** - Mitosis (a), apoptosis (b), and enzymatic activity (c-e) parameters of rats submitted to Partial Hepatectomy (CG), and *Coleus forskohlii* + Partial Hepatectomy (TG). CG 24 hs, CG 48 hs: Groups examined 24 and 48 h after partial hepatectomy, respectively; TG 24 h, TG 48 h: *Coleus forskohlii* - treated groups examined 24 and 48 h after partial hepatectomy, respectively (n=5).
No other studies investigating the relationship between oral administration of a *C. forskohlii* extract and partial hepatectomy were detected in the literature, showing that the present study is original. The treatment with 40 mg/kg/day for 10 days used here appears not to have interfered significantly with the hepatic function of treated animals.

It should be pointed out that this plant extract is being commercialized with the objective of aiding weight loss and that there are data proving that its use together with a low-calorie diet can be useful for the management of metabolic risk factors. However, the extract has shown to induce hepatic drug metabolizing enzymes and to interact with co-administered drugs such as warfarin, so that its use should be indicated with caution and under medical supervision.

Although the present study was conducted on experimental animals, while it would be of fundamental importance to conduct clinical studies on humans, the present results suggest that, if a patient who regularly uses this phytotherapeutic agent for other purposes, such as weight loss, for example, should be submitted to a surgical intervention in the liver, *Coleus forskohlii* probably would not interfere with the functional reestablishment of the liver after the surgery.

## Conclusions

The results obtained after treatment with *Coleus forskohlii* showed that the mitotic and apoptotic indices and the concentrations of AST, ALT and alkaline phosphatase did not differ significantly between the experimental animals and their controls. In addition, no areas of fibrosis were observed in the hepatic tissue of treated animals. Thus, we conclude that treatment with *Coleus forskohlii* did not interfere with the course of hepatic hyperplasia. The present study was conducted on experimental animals, but it is of fundamental importance to conduct studies on humans. Our results suggest that *Coleus forskohlii* probably would not interfere with the functional reestablishment of the liver after a surgical intervention.

## References

1. Kavitha C, Rajamani K, Vadivel E. Coleus forskohlii. A comprehensive review on morphology, phytochemistry and pharmacological aspects. J Med Plants Res. 2010;4(4):278-85.
2. Alabashi RH, Melzing MF. Plectranthus barbatus: a review of phytochemistry, ethnobotanical uses and pharmacology – part 1. Planta Med. 2010;76(7):653-61. doi: 10.1055/s-0029-1240898
3. Ganash M, Sultan Q. Phenolic acids and biological activities of Coleus forskohlii and Plectranthus barbatus as traditional medicinal plants. Int J Pharmacol. 2018;4(6):856-65. doi: 10.3923/ijip.2018.856.865
4. Ma C, Zou L, Xia Y, Tu Y, Xue D, Yang Y, Liu D, Liu Y, Wu H, Dan H, You P1. Extracts of Coleus forskohlii relieve cough and asthma symptoms via modulating inflammation and the extracellular matrix. J Cell Biochem. 2019;120(6):9648-55. doi: 10.1002/jcb.28243
5. Fatima N, Sultan A. Renoprotective and anti-oxidant effects of Coleus forskohlii against gentamicin induced nephrotoxicity in albino wistar rats. Shadan Womens College of Pharmacy, Department of Pharmacology, Hyderabad, India. Acta Pharm Sci. 2018;56(2):67-84. doi: 10.23893/1307-2080APS.05612
6. Bauer K, Dietersdorfer F, Sertl K, Kaik B, Kaik G. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clin Pharmacol Ther. 1993;53:76–83. doi: 10.1038/clpt.1993.11
7. Alabashi RH, Melzing MF. Plectranthus barbatus: a review of phytochemistry, ethnobotanical uses and pharmacology – part 2. Planta Med. 2010;76(8):753-65. doi: 10.1055/s-0029-1240919
8. Illiano M, Sapio L, Ciaifa IL, Chiosi EM, Spina A, Naviglio S. Forskolin sensitizes pancreatic cancer cells to gemcitabine via Stat3 and Erk1/2 inhibition. AIMS Mol Sci. 2017;4:224-40. doi: 10.3934/molsci.2017.2.224
9. Guo X, Bai X, Jianfeng L, Wang H. Forskolin protects against cisplatin-induced ototoxicity by inhibiting apoptosis and ROS production. Biomed Pharmacother. 2018;99:530-6. doi: 10.1016/j.biopha.2018.01.080
10. Brasil CM. Diretriz brasileira para o cuidado e a utilização de animais em atividades de ensino ou de pesquisa científica-DBCA. Resolução Normativa MCTI; 2016.
11. Barros PP, Gonçalves GMS, Silva GH, Bastos MCVD, Ramos LN, Fernandes MM. Capsiccate treatment in liver surgeries may compromise its recovery. Acta Cir Bras. 2018;33(5):439-45. doi: 10.1590/0102-86502018005000006
12. Higgins GM, Anderson RM. Experimental pathology of the liver: I. Restoration of the liver of the white rat following partial surgical removal. Arch Pathol. 1931;12:186-202.
13. Geng D, Li C, Yi LT, Weng LJ, Han YY. Hepatoprotective effects of Coleus forskohlii (wild.) Briq. against carbon tetrachloride-induced hepatotoxicity in mice. J Chem Pharm Res. 2014;6:130-5.
14. Jyothi Y, Kumar K, Reddy S, Dey T. Effect of hexane extract of Coleus forskohlii on chemically induced liver damage. Res J Pharmacol Pharmacodynamics. 2010;2(6):380-3.
15. Virgona N, Taki Y, Yamada S, Umegaki K. Dietary Coleus forskohlii extract generates dose-related hepatotoxicity in mice. J Appl Toxicol. 2013;33(9):924-32. doi: 10.1002/jat.2770
16. Malavizhi A, Srinivasan S. Effect of Coleus forskohlii root extracts on liver marker enzymes. Indian J Biotech Pharm Res. 2015;4(3):158.
Pretreatment of hepatetctomized rats with Coleus forskohlii did not interfere with the course of hepatic hyperplasia
Barros PP et al.

Acta Cir Bras. 2019;34(6):e201900607

Correspondence:
Pedro Paulo Barros
Faculdade de Ciências Farmacêuticas
Avenida John Boyd Dunlop, s/n
13060-904 Campinas – SP Brasil
Tel.: (55 19)3343-6865
barrospp@puc-campinas.edu.br

Received: Feb 22, 2019
Reviewed: Apr 20, 2019
Accepted: May 23, 2019

Conflict of interest: none
Financial source: none

1Research performed at the Laboratory of Biological Tests, Faculty of Nutrition, Pontifícia Universidade Católica de Campinas (PUC-Campinas), Brazil.

17. Jakopin Ž. Risks associated with fat burners: a toxicological perspective. Food Chem Toxicol. 2019;123:205-24. doi: 10.1016/j.fct.2018.10.051
18. Astell KJ, Mathai ML, Su XQ. A review on botanical species and chemical compounds with appetite suppressing properties for body weight control. Plant Foods Hum Nutr. 2013;68:213–21. doi: 10.1007/s11130-013-0361-1
19. Loftus H, Astell K, Mathai M, Su X. Coleus forskohlii extract supplementation in conjunction with a hypocaloric diet reduces the risk factors of metabolic syndrome in overweight and obese subjects: a randomized controlled trial. Nutrients. 2015;7(11):9508-22. doi: 10.3390/nu7115483
20. Yokotani K, Chiba T, Sato Y, Taki Y, Yamada S, Shinozuka K, Umegaki K. Hepatic cytochrome P450 mediates interaction between warfarin and Coleus forskohlii extract in vivo and in vitro. J Pharm Pharmacol. 2012;64:1793–801. doi: 10.1111/j.2042-7158.2012.01563.x
21. Yokotani K, Chiba T, Sato Y, Nakanishi T, Murata M, Umegaki K. Influence of dietary macronutrients on induction of hepatic drug metabolizing enzymes by Coleus forskohlii extract in mice. J Nutr Sci Vitaminol. 2013;59(1):37-44. doi: 10.3177/jnsv.59.37

Acknowledgement

To Pontifícia Universidade Católica de Campinas for support by means of research incentives.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.